| Patient | Audre Lorde |
|---|---|
| Date of birth | 1934-02-18 |
| Identifiers | MRN HR-ML016-SYN-TD; SSN (made up) 000-16-2937 |
| Document date | 1979-03-30 |
| Author | Naomi Fairweather, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Survivorship follow-up on the day of the medical oncology consultation. [S]
Ms. Lorde returns three weeks after her first visit here. She saw Dr. Lozano of medical oncology this morning. She has taken tamoxifen every day for five months. She has three or four hot flashes a day and is woken by one on one or two nights a week; she would rather manage them without another medicine if she can. Her periods continue every four to five weeks, a little lighter, with no bleeding between them. She has no leg swelling, chest pain, or breathlessness. The mastectomy scar is comfortable, and she has no arm heaviness or swelling. She is writing and walking daily and feels steady in mood. She is settled in her decisions after surgery: she chose a flat closure and does not want reconstruction or an external prosthesis. [S]
| Element | Detail |
|---|---|
| Interval change | Medical oncology consultation this morning |
| Tamoxifen | Five months, taken daily |
| Vasomotor symptoms | Three or four hot flashes a day; wakes one or two nights a week |
| Gynecologic | Periods every four to five weeks; no intermenstrual bleeding |
| Arm and chest wall | No swelling, heaviness, or pain |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, weight loss, or unexplained tiredness |
| Endocrine | Positive | Hot flashes three or four times a day |
| Genitourinary | Negative | No abnormal vaginal bleeding or discharge |
| Cardiovascular | Negative | No leg swelling, calf pain, or chest pain |
| Respiratory | Negative | No breathlessness or cough |
| Musculoskeletal | Negative | No bone pain; full use of the right arm |
| Psychiatric | Negative | Mood steady; sleeping well on most nights |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years | One tablet once daily | Oral route | 1978-10-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-03-30 | Body height | 168 | cm | S |
| 1979-03-30 | Body weight | 72.4 | kg | S |
| 1979-03-30 | Body mass index (BMI) [Ratio] | 25.7 | kg/m2 | S |
| 1979-03-30 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1979-03-30 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1979-03-30 | Heart rate | 72 | /min | S |
| 1979-03-30 | Respiratory rate | 14 | /min | S |
| 1979-03-30 | Body temperature | 36.6 | Cel | S |
| 1979-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
Vital signs recorded on 1979-03-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Breasts and chest wall | Right chest wall flat, scar healed, no nodules; left breast without masses |
| Lymph nodes | No axillary or supraclavicular nodes |
| Extremities | Arm circumference 10 cm above the elbow 29.0 cm on each side; right shoulder full range of motion; calves soft and non-tender |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1931 breast cancer and mastectomy | active | confirmed | C50.411 | S — Synthetic tumor details and treatment; the diagnosis and the mastectomy are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesis | active | confirmed | Z90.11 | S — Synthetic coding of the documented mastectomy; the decision about a prosthesis echoes her documented choice and is respected as her own. |
| Long-term use of tamoxifen as adjuvant endocrine therapy | active | confirmed | Z79.810 | S — Synthetic treatment status. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No symptoms or signs of recurrence; chest wall and left breast normal |
| Medication safety | Tamoxifen adherence and side effects | Every visit | Completed today | Taken daily for five months; no missed doses |
| Survey | Vasomotor symptom assessment | Periodically on endocrine therapy | Completed today | Three or four hot flashes a day; non-drug measures started |
| Examination | Abnormal vaginal bleeding inquiry on tamoxifen | Every visit | Completed today | No bleeding between periods; yearly gynecologic assessment due at the autumn preventive visit |
| Examination | Venous thromboembolism symptom inquiry on tamoxifen | Every visit | Completed today | No leg swelling, calf pain, or breathlessness |
| Medication safety | Interacting medicines with tamoxifen (strong CYP2D6 inhibitors) | At each medicine change | Completed today | No interacting medicine; if a hot-flash medicine is needed, venlafaxine rather than paroxetine or fluoxetine |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | No swelling; arm circumferences equal; risk is low after sentinel node biopsy alone; counseled to report heaviness or swelling |
| Survey | Distress, depression, and anxiety screen (PHQ-9 and GAD-7) | At periodic intervals | Up to date | PHQ-9 4 and GAD-7 3 three weeks ago; next at the three-month visit |
| Survey | Fatigue, cognitive concerns, and sexual or vaginal symptoms | At each visit or periodically | Completed today | No fatigue or memory concerns; no vaginal dryness or pain |
| Laboratory | Routine blood counts, chemistry, liver tests, and tumor markers (CEA, CA 15-3, CA 27.29) | Not recommended in asymptomatic stage I to III survivors | Not indicated | No symptoms to prompt testing; none ordered |
| Imaging | CT, bone scan, PET, or other imaging for distant spread | Not recommended in asymptomatic survivors | Not indicated | No symptoms; not ordered |
| Imaging | Diagnostic mammogram of the left breast | Yearly after mastectomy | Due | In September, one year after the diagnostic mammogram |
| Imaging | Breast MRI | Yearly only if high-risk criteria are met (BRCA1 or BRCA2, chest radiation at 10 to 30, lifetime risk 20 percent or more) | Not indicated | No high-risk criterion known; to be revisited if germline testing finds a pathogenic variant |
| Imaging | Bone density (DXA) | Every 2 years on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopause | Not indicated | Premenopausal on tamoxifen alone; bone health by diet, vitamin D, and weight-bearing exercise |
| Imaging | Echocardiogram (LVEF) | During and after trastuzumab; after anthracycline as indicated | Not indicated | No trastuzumab or anthracycline given |
| Referral | Germline genetic testing at diagnosis, for breast cancer diagnosed at 65 or younger | Once, at diagnosis | Deferred | Not offered at diagnosis by her previous care team, a deviation from the guideline found at intake. No harm is known: the result would not have changed her surgery, which she chose, but it could change surveillance and the advice to relatives. Corrective action: genetic counseling requested today, as Dr. Lozano advised |
| Referral | Genetic counseling | Once | Referred | Request sent today; on the waiting list |
| Referral | Medical oncology | Shared survivorship care | Completed today | Seen this morning; recommendations in the consultation note |
| Self-management | Healthy lifestyle counseling | Every visit | Completed today | Walking about 30 minutes most days; goal of 150 minutes a week plus strength exercise twice a week; alcohol rarely; never smoker |
Goal progress:
Guideline basis: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024 (2024); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Survivorship visit in three months with PHQ-9 and GAD-7. Genetic counseling when offered. Call for abnormal bleeding, leg swelling, a new lump, bone pain, or arm swelling. Next scheduled visit 1979-06-29: three-month survivorship visit on tamoxifen. [S]